Press Releases Items Per Page 102550 News Category FinancialGeneral Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 FDA Approval of Cimzia(R) for Crohn's Disease Represents Latest Milestone for Nektar's PEGylation Technology Platform Apr 23, 2008 Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting Apr 14, 2008 Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings Apr 10, 2008 Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients Apr 09, 2008 Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results Feb 27, 2008 Nektar to Announce 2007 Year-End Financial Results on Wednesday, February 27, 2008, After Close of U.S.-Based Financial Markets Feb 21, 2008 Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization Feb 12, 2008 Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Company's Board of Directors Feb 12, 2008 Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City Jan 29, 2008 Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction Jan 08, 2008 Pagination First page « first Previous page ‹ previous … Page 42 Page 43 Page 44 Page 45 Current page 46 Page 47 Page 48 Page 49 Page 50 … Next page next › Last page last »